Evolus (EOLS) Stock Forecast & Price Target

Evolus Inc. reported total net revenue of $69.4 million in its latest fiscal period, reflecting a year-over-year increase of 3.7%, largely fueled by higher Jeuveau volumes and the successful launch of the Evolysse dermal filler line. The company anticipates that Evolysse could contribute approximately $33 million, or 10-12% of its 2025 top-line guidance, based on strong initial demand. Moreover, market trends indicate significant growth potential as younger consumers increasingly embrace aesthetic treatments, suggesting a favorable environment for Evolus’s expansion in the self-pay aesthetic market.

Evolus Inc has experienced a decline in adjusted gross margins, dropping to 66.5% from 71.5% year-over-year, primarily driven by an increased proportion of international sales and introductory pricing strategies. The company has revised its 2025 net revenue guidance downward to $295-$305 million, a significant reduction from the previous estimate of $345-$355 million, reflecting a slowdown in projected growth from 30%-33% to only 11%-15%. Furthermore, Jeuveau's sales in 2Q25 reached $59 million, marking a year-over-year decline for the first time since its launch in 2019, attributed to weakened consumer sentiment and ongoing pressures in the U.S. toxin market.